about
Safety of extended treatment with anakinra in patients with rheumatoid arthritisIncidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritisRisk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Rheumatoid factor by laser nephelometry and Waaler-Rose assay: prognostic value in patients with recent-onset rheumatoid arthritis.Lymphoproliferative malignancy in rheumatoid arthritis: a study of 20 cases.Rheumatoid arthritis and malignant histiocytosis of the intestine.Remission of arthritis and radiological improvement after combination therapy for non-Hodgkin's lymphoma in a patient with rheumatoid arthritis undergoing treatment with D-penicillamineEvidence for oligoclonal B cell expansion in the peripheral blood of patients with rheumatoid arthritis.Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up studyMortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients.Prognostic significance of paraproteinaemia in rheumatoid arthritis.Rheumatological manifestations of haematological diseases.Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.Review article: does the use of immunosuppressive therapy in inflammatory bowel disease increase the risk of developing lymphoma?Ten year mortality and causes of death in patients with rheumatoid arthritis.Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort.Risk of multiple myeloma in rheumatoid arthritis: a meta-analysis of case-control and cohort studies.Epstein-Barr virus-positive multiple myeloma developing after immunosuppressant therapy for rheumatoid arthritis: a case report and review of literature.Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.Risk of lymphoma in patients with RA treated with anti-TNFalpha agents.Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007The world of biologics.Risk of nonmelanoma skin cancer with azathioprine use.Cancer morbidity in rheumatoid arthritis: role of estrogen metabolitesRheumatoid arthritis, malignancy, and paraproteins.Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort.Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study.Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre.Case-control study of multiple myeloma and farming.Cancer morbidity in rheumatoid arthritis patients treated with Proresid or parenteral gold.Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma.Association between azathioprine therapy and lymphoma in rheumatoid disease.
P2860
Q24675209-B54A9497-0122-4A97-83D6-81661D3E7C9DQ24675306-EF312321-E949-4C18-A4A9-8D81B289178DQ30240212-E10B5E23-9133-4FC9-AAB9-7A4AF2B1AB12Q33224257-A0B7E2F6-E96F-4149-923E-BC6C03FC4D2FQ33555200-637A69F3-6ECB-4024-AF97-D2DB1039933CQ33555484-0B53AE6E-3B29-4816-896A-82CCC279A060Q33556067-7B400AAC-073B-48F8-9736-3532F6004C75Q33557102-C82116D7-4078-44FE-96E9-DC81B5F84757Q33561291-1CA0624F-DF7F-48C7-AA94-6D31E6F66A44Q33562682-13DB1DD3-3D6A-4812-A140-997B39524481Q33563584-1AF707D7-9592-4D69-8461-4CF169355E8DQ33578386-A3F5BFF9-0702-4846-9705-D80FC3609B39Q33873620-8A841D7F-C851-4922-B5DC-4F3AF88199E4Q34458932-6D81299A-EA27-45A4-9C83-99BE7137DC69Q34485318-F94F409F-752F-45C6-B60E-5429D38D32ACQ34628409-3BBE38B4-F34A-40B9-A542-5EC44890FF9FQ35120199-6A248132-DE68-4EB1-91CE-28BC7CC68277Q35406750-8F875A87-44A8-4D11-8B52-90EFB2AD63C3Q35553451-F903761D-2006-4F69-A205-3A3D0BDEF122Q35554823-B5B2B59F-A376-49E6-9C86-0310B5790210Q35555473-2F63E327-46AB-4A63-AAD3-F06C47F1508FQ35579352-B9ACF1C2-7C05-4B1B-B210-271C0FF67117Q35579517-33225945-98B8-4808-82DB-E5C0B88E20B6Q35638252-C126C9FF-90CD-47B5-97E3-BC90A1B8A23CQ36171750-B43B4382-62E4-4BD9-B31B-EA8A47A577A1Q36458132-13CD0E20-B601-4A66-928D-24D650CD89A3Q37126243-A630C22A-896C-4847-9F69-40C0879D5A5BQ37212423-A30B9C5A-C0EA-460D-8953-24C3C4875633Q37993069-01FCE6B0-1BBE-4222-ABC2-F8462B3E1E53Q38401295-F1BA60C2-88FB-4C8D-A14B-604029146CEAQ38645434-4EEB1524-FF7B-4555-B97B-3BE5D8288974Q38689671-2EB60B48-20AB-4DCE-8181-8361A494FEEBQ40805298-D8C725A8-DF9D-4EAC-94A8-AED070D51879Q44345637-BAD2FED7-7B8A-43FA-BCB7-04F491114A53Q45163842-8DD2D4E5-02FB-44A6-942C-FC6D5D8534D8Q55167085-2D9B34B2-4C71-4822-B632-1BF4A107BF6D
P2860
description
1984 nî lūn-bûn
@nan
1984 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1984 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
name
Cancer morbidity in rheumatoid arthritis.
@ast
Cancer morbidity in rheumatoid arthritis.
@en
Cancer morbidity in rheumatoid arthritis.
@nl
type
label
Cancer morbidity in rheumatoid arthritis.
@ast
Cancer morbidity in rheumatoid arthritis.
@en
Cancer morbidity in rheumatoid arthritis.
@nl
prefLabel
Cancer morbidity in rheumatoid arthritis.
@ast
Cancer morbidity in rheumatoid arthritis.
@en
Cancer morbidity in rheumatoid arthritis.
@nl
P2093
P2860
P356
P1476
Cancer morbidity in rheumatoid arthritis.
@en
P2093
P2860
P304
P356
10.1136/ARD.43.2.128
P407
P577
1984-04-01T00:00:00Z